£120.74

This is the usual price. Wait for it to drop, or tell us your number.

£121 today · usual range £112–£121 · best ever £112

Springer The Challenge of CMC Regulatory Compliance for Biopharmaceuticals

Amazon

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 63 days · 63 data points (no recent data)

Historical
Generating forecast…
£120.95 £110.97 £113.15 £115.33 £117.50 £119.68 £121.86 22 August 2026 06 September 2026 22 September 2026 07 October 2026 23 October 2026
View at Amazon ↗

Price data last checked 28 day(s) ago - will refresh soon

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↑ Price chart
when this has been cheap or pricey
↑ Forecast
where the price is heading next
↓ Statistics
all-time high & low, recent range
↑ Price alert
name your number, we'll email you

Price Distribution

Price distribution over 63 days • 3 price levels

Days at Price
Current Price
26 days 19 days 18 days · current 0 7 13 20 26 £112 £119 £121 Days at Price

Price Analysis

Most common price: £112 (26 days, 41.3%)

Price range: £112 - £121

Price levels: 3 different prices over 63 days

Description

Biopharmaceuticals (i.e., biological medicines sourced from genetically-engineered living systems) for treatment of human diseases have become a significant percentage of the pharmaceutical industry. And not just the recombinant DNA-derived proteins and monoclonal antibodies (both from the innovators and biosimilars); but now, an increasing awareness of the importance of gene therapy and genetically engineered cellular medicinal products. These biopharmaceuticals are being developed by many companies whose Chemistry, Manufacturing & Control (CMC) teams have varying degrees of familiarity or experience with the CMC strategy and regulatory compliance requirements for these challenging products. Companies clearly plan out the strategy for their clinical study plans, but frequently, the development of a strategy for CMC is an afterthought. Coupled with the complexity of the biopharmaceutical manufacturing processes and products, and this can be a recipe for disaster. The third edition of this book provides insights and practical guidance for the CMC teams to develop an acceptable cost-effective, risk-based CMC regulatory compliance strategy for all biopharmaceuticals (recombinant proteins, monoclonal antibodies, genetically engineered viruses and genetically engineered human cells) from early clinical stage development through market approval. The third edition of this book provides added coverage for the biosimilars, antibody drug conjugates (ADCs), bispecific antibodies, genetically engineered viruses, and genetically engineered cells. This third edition of the book also addresses the heightened pressure on CMC regulatory compliance timelines due to the introduction of expedited clinical pathways moving the clinical development closer to a seamless phase process (e.g., FDA Breakthrough Therapy designation, CBER Regenerative Medicine Advanced Therapy (RMAT) designation, EMA Priority Medicines (PRIME) designation). The Challenge of CMC Regulatory Compliance for Biopharmaceuticals is essential, practical information for all pharmaceutical development scientists, Manufacturing and Quality Unit staff, Regulatory Affairs personnel, and senior management involved in the manufacture of biopharmaceuticals.

Product Specifications

Format
hardcover
Domain
Amazon UK
Release Date
20 May 2019
Listed Since
19 January 2019

Barcode

No barcode data available

Similar Products You Might Like

Biosimilars: Regulatory, Clinical, and Biopharmaceutical Development: 34 (AAPS Advances in the Pharmaceutical Sciences Series, 34)
83% match

Biosimilars: Regulatory, Clinical, and Biopharmaceutical Development: 34 (AAPS Advances in the Pharmaceutical Sciences Series, 34)

Springer

£124.31 23 Oct 2026
Challenges in Protein Product Development: 38 (AAPS Advances in the Pharmaceutical Sciences Series, 38)
83% match

Challenges in Protein Product Development: 38 (AAPS Advances in the Pharmaceutical Sciences Series, 38)

Springer

£243.51 01 Nov 2026
An Introduction to Bioanalysis of Biopharmaceuticals: 57 (AAPS Advances in the Pharmaceutical Sciences Series, 57)
82% match

An Introduction to Bioanalysis of Biopharmaceuticals: 57 (AAPS Advances in the Pharmaceutical Sciences Series, 57)

Springer

£97.88 12 Sep 2026
Biosimilars: Design and Analysis of Follow-on Biologics: 60 (Chapman & Hall/CRC Biostatistics)
81% match

Biosimilars: Design and Analysis of Follow-on Biologics: 60 (Chapman & Hall/CRC Biostatistics)

CRC Press

£150.16 29 Oct 2026
Cell Free Synthesis of Biologics: A Comprehensive Guide
81% match

Cell Free Synthesis of Biologics: A Comprehensive Guide

Elsevier

£135.76 23 Oct 2026
Stem Cell Drugs - A New Generation of Biopharmaceuticals (Stem Cells in Clinical Applications)
81% match

Stem Cell Drugs - A New Generation of Biopharmaceuticals (Stem Cells in Clinical Applications)

Springer

£74.77 27 Oct 2026
Cost-Contained Regulatory Compliance: For the Pharmaceutical, Biologics, and Medical Device Industries
81% match

Cost-Contained Regulatory Compliance: For the Pharmaceutical, Biologics, and Medical Device Industries

Wiley

£84.22 27 Oct 2026
Immunogenicity of Biopharmaceuticals: VIII (Biotechnology: Pharmaceutical Aspects, VIII)
81% match

Immunogenicity of Biopharmaceuticals: VIII (Biotechnology: Pharmaceutical Aspects, VIII)

Springer

£110.73 22 Oct 2026
Engineering Biomaterials for Regenerative Medicine: Novel Technologies for Clinical Applications
81% match

Engineering Biomaterials for Regenerative Medicine: Novel Technologies for Clinical Applications

Springer

£113.78 22 Oct 2026
Bispecific Antibodies
81% match

Bispecific Antibodies

Springer

£129.06 29 Oct 2026
Rift-lines within european regulatory framework for biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and ... Framework for Biosimilars When Taking
81% match

Rift-lines within european regulatory framework for biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and ... Framework for Biosimilars When Taking

Books on Demand

£103.19 08 Sep 2026
Biosafety in Industrial Biotechnology
81% match

Biosafety in Industrial Biotechnology

Springer

£142.96 25 Oct 2026
Microbial Engineering for Therapeutics
80% match

Microbial Engineering for Therapeutics

Springer

£147.14 02 Nov 2026
Infectious Complications in Biologic and Targeted Therapies
80% match

Infectious Complications in Biologic and Targeted Therapies

Springer

£80.77 20 Oct 2026
Microbiological Contamination Control in Pharmaceutical Clean Rooms
80% match

Microbiological Contamination Control in Pharmaceutical Clean Rooms

CRC Press

£115.05 17 Sep 2026
Stem Cells in Regenerative Medicine: Science, Regulation and Business Strategies
80% match

Stem Cells in Regenerative Medicine: Science, Regulation and Business Strategies

Wiley

£135.64 20 Oct 2026
Approaching China's Pharmaceutical Market: A Fundamental Guide to Clinical Drug Development
80% match

Approaching China's Pharmaceutical Market: A Fundamental Guide to Clinical Drug Development

Springer

£113.73 23 Oct 2026
Nonclinical Evaluation Studies of Cellular and Gene Therapy Products: Strategies, Models, and Regulatory Frameworks
80% match

Nonclinical Evaluation Studies of Cellular and Gene Therapy Products: Strategies, Models, and Regulatory Frameworks

Elsevier

£225.89 23 Oct 2026
3D Bioprinting and Bio-Regenerative Medicine for Personalized Oncology: Innovations for Personalized Oncology
80% match

3D Bioprinting and Bio-Regenerative Medicine for Personalized Oncology: Innovations for Personalized Oncology

Elsevier

£137.99 23 Oct 2026
Handbook of Process Chromatography: A Guide to Optimization, Scale Up, and Validation
80% match

Handbook of Process Chromatography: A Guide to Optimization, Scale Up, and Validation

Elsevier

£140.00 22 Oct 2026
Next Generation Antibody Drug Conjugates (ADCs) and Immunotoxins (Milestones in Drug Therapy)
80% match

Next Generation Antibody Drug Conjugates (ADCs) and Immunotoxins (Milestones in Drug Therapy)

Springer

£108.78 22 Oct 2026
Safety, Ethics and Regulations (Stem Cells in Clinical Applications)
80% match

Safety, Ethics and Regulations (Stem Cells in Clinical Applications)

Springer

£108.75 30 Oct 2026
Life Sciences Industry: From Laboratories to Commercialization of Research: 2 (New Paradigms of Living Systems, 2)
80% match

Life Sciences Industry: From Laboratories to Commercialization of Research: 2 (New Paradigms of Living Systems, 2)

Springer

£91.52 30 Oct 2026
80% match

Molecular and Cellular Biology Approaches and Applications in Modern Drug Discovery

Elsevier

£157.99 22 Oct 2026